TB Biosciences Raises $1.5M in Series A Financing | GenomeWeb

NEW YORK (GenomeWeb News) – TB Biosciences, which is developing a point-of-care test for the detection of tuberculosis, said today it has closed on its Series A financing round, raising $1.5 million.

The financing will be used to support product development and clinical trials.

Originate Ventures led the round, which also included investors Ben Franklin Technology Partners of Northeastern Pennsylvania and the NYU Innovation Venture Fund. With recent funding from the National Institutes of Health, new funds total $2.5 million, the Bethlehem, Penn.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.